Medical/Pharmaceuticals
HKBU clinches four gold medals at the 15th International Invention Fair in the Middle East
HONG KONG, March 3, 2025 /PRNewswire/ -- Hong Kong Baptist University (HKBU)
won four gold medals at the 15th International Invention Fair in theMiddle East
(IIFME) held inKuwait from 16 to 19 February. It was the first time that HKBU
participated in the event.
2025-03-04 12:10
2557
DeepQure Advances Global Clinical Trials for Innovative RDN Technology
SEOUL, South Korea, March 3, 2025 /PRNewswire/ -- Breaking Barriers in Hypertension Treatment DeepQure Inc., a pioneering medical device startup, is revolutionizing the treatment of resistant hypertension with its innovative extravascular (laparoscopic approach) renal denervation (RDN) device, Hy...
2025-03-04 09:46
3198
Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma) Initiate Phase 3 Registration Trial in China for Submental Fat Reduction ("double chin")
REROVOT, Israel, March 3, 2025 /PRNewswire/ -- Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phase 3 study initiation inChina for the treatment of fat reduction in the submental area. Submental fat...
2025-03-04 09:00
2466
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China, March 3, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced thatthe first patient has been successfully dosed in the global multicenter P...
2025-03-04 08:10
4199
METiS Pharmaceuticals Appoints Mark Herbert as Chief Business Officer
HANGZHOU, China, March 3, 2025 /PRNewswire/ -- METiS Pharmaceuticals, a clinical-stage, AI-driven biotechnology company specializing in innovative drug delivery technologies, today announced the appointment ofMark Herbert as Chief Business Officer (CBO), effectiveJanuary 22, 2025. In this role, M...
2025-03-03 16:20
2817
BioRes Ruizhi BLC Implant System Showcased in China, Addressing Rising Demand for High-quality Implants
WALNUT, Calif., March 3, 2025 /PRNewswire/ -- BioRes Dentech Inc. showcased its Ruizhi BLC Implant System at Dental South China 2025, a premium product line jointly launched by BioRes Dentech Inc. and Besmile, designed exclusively for China's market. With advanced bone preservation technology and ...
2025-03-03 15:00
2380
CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) ofChina's National Medical ...
2025-03-03 08:15
3055
Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025
SAN DIEGO, March 2, 2025 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, proudly...
2025-03-03 02:00
3187
EMSRUN Medical Strengthens Middle East Footprint with Innovative Emergency Care Solutions at IDEX & NAVDEX 2025
ABU DHABI, UAE, March 1, 2025 /PRNewswire/ -- EMSRUN Medical
2025-03-01 20:06
4242
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases
Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H 2025 BOSTON, Feb. 28, 2025 /PRNewswire/ -- Ba...
2025-02-28 22:58
5915
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, has a...
2025-02-28 08:15
3012
Lunit Achieves Milestone at ECR 2025: 13 Oral Presentations Among 15 AI Studies, Demonstrating Unmatched Clinical Impact
* Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research * Key studies demonstrate AI's capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, an...
2025-02-27 22:00
3250
So-Young Receives Approval to Transfer to Nasdaq Capital Market and Extension of Minimum Bid Price Compliance Period
BEIJING, Feb. 27, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that onFebruary 25, 2025, the...
2025-02-27 18:47
4219
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies inAustralia. AK138D1, a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate)...
2025-02-27 16:58
2548
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 12:30
2789
Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the appointment ofCraig Hadfield as the new CEO of its subsidiary, Volpara Health Technologies. ...
2025-02-26 22:00
3314
Neurophet Presented Three Research Abstracts on Personalized tDCS at International Brain Stimulation Conference
- Showcased core technology and products for personalized tDCS at the conference inKobe, Japan - Presented clinical outcomes in disorders of consciousness, upper extremity function in patients with sub-acute and chronic stroke, and post-stroke dysphagia SEOUL, South Korea, Feb. 26, 2025 /PRNews...
2025-02-26 22:00
3578
Visionary Holdings: Deeply Responding to the Concerns of the Capital Market and Demonstrating Solid Development Strength
TORONTO, Feb. 26, 2025 /PRNewswire/ -- Recently, in response to numerous questions from the capital market regarding Visionary Holdings (Nasdaq Stock Code: GV), the company has specifically issued this press release with the aim of providing a comprehensive and clear response to these concerns an...
2025-02-26 22:00
4155
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development...
2025-02-26 18:33
3117
Ping An Health Launches "Ping An Xin Yi" AI Doctor Assistant Service to Enhance Accessibility and Satisfaction in Medical Services
HONG KONG and SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently announced the launch of "Ping An Xin Yi ," an AI-powered digital doctor service integrated within its Pi...
2025-02-26 17:06
3527
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 292 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 281 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 279 media titles]
2026-10-15 12:59
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Most Read
Amap and Sands China mark the delivery of the first Tutu robots, with expected indoor navigation and 3D resort previews
2026-10-10 16:43
15970
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
14830